AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17878479
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg plus docetaxel
Trial: 17878479
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg plus docetaxel
Trial: 15135147
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (1500 mg daily for 12 weeks)
Trial: 15135147
Drug: Placebo (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1500 mg daily for 12 weeks)
Trial: 10690829
Drug: Intraoperative mitomycin‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative mitomycin‐C (0.3 mg/ml) applied under both flaps (group 3)
Trial: 10690829
Drug: Intraoperative mitomycin‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the scleral flap (group 2)
Trial: 10690829
Drug: Intraoperative mitomycin‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the conjunctival flap (group 1)
Trial: 9368726
Drug: Simultaneous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous chemotherapy with radiotherapy
Trial: 3771854
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin in combination with 0.5% minoxidil
Trial: 3771854
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin alone
Trial: 29980818
Drug: Cannabis decoction
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis decoction (200 ml)
Trial: 29980818
Drug: Cannabis oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis oil (1 ml)
Trial: 24996447
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) administered one pill a day for 63 days
Trial: 24996447
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) plus Dan'e mixture (30 g/day for 30 days)
Trial: 22799753
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) treatment administered twice daily for 52 weeks
Trial: 20141396
Drug: No antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antidepressant
Trial: 18031326
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, 1 mg/m²/day for 12 months
Trial: 10834421
Drug: human regular
RxNorm normalized name: Human regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human regular insulin therapy
Trial: 10408729
Drug: MN rgp120
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN rgp120 HIV-1 vaccine
Trial: 10408729
Drug: IIIB rgp120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIIB rgp120 HIV-1 vaccine
Trial: 8807200
Drug: Priming immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming immunization with IIIB rgp120 followed by booster injections of MN rgp120
Trial: 8807200
Drug: MN rgp120
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN rgp120 HIV-1 vaccine given alone
Trial: 8807200
Drug: HIV-1IIIB-based gp160
RxNorm normalized name: HIV gp160 vaccine
DrugBank: VaxSyn (DB17827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1IIIB-based gp160 vaccines
Trial: 4029016
Drug: Temocillin 250
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin 250 mg/h
Trial: 4029016
Drug: Temocillin 750
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin 750 mg/h
Trial: 4029016
Drug: Probenecid (blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (blocking tubular excretion)
Trial: 28353022
Drug: 0.2% morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% morphine
Trial: 28353022
Drug: 0.4% morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% morphine
Trial: 28353022
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (0.2% morphine, 0.4% morphine, placebo)
Trial: 22456699
Drug: Usual practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual practice dysphagia therapy
Trial: 19843655
Drug: Perphenazine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (8 to 32 mg daily for 14 to 600 days)
Trial: 17506736
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (1 ml of 0.25% bupivacaine on each side)
Trial: 17506736
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with pethidine (1 ml of 0.25% bupivacaine and 0.25 mg.kg(‐1) body weight pethidine)
Trial: 15652871
Drug: Nocturnal urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal urinary excretion of 6‐sulphatoxymelatonin in patients with autism
Trial: 11308250
Drug: DTIC (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4)
Trial: 11308250
Drug: DTIC (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4) plus IL-2 (4.5 MIU/m² for 3 hours i.v. on day 3; 9.0 MIU/m² i.v. day 3/4; 4.5 MIU/m² s.c. days 4 to 7)
Trial: 9447531
Drug: Surfactant dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant dosing through a proximal sideport adapter
Trial: 9447531
Drug: Surfactant dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant dosing through a double-lumen endotracheal tube
Trial: 165796
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride treatment
Trial: 2405806
Drug: Imipramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine treatment combined with intensive group psychotherapy
Trial: 2405806
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment combined with intensive group psychotherapy
Trial: 30824256
Drug: TAU+APP (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU+APP (treatment as usual with app access)
Trial: 30824256
Drug: TAU (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (treatment as usual without app access)
Trial: 25494297
Drug: Low-iodine-load protocol
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Trial: 25494297
Drug: Moderate-iodine-load protocol
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Trial: 25494297
Drug: High-iodine-load protocol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-iodine-load protocol (600 mg iodine per kg at 120 kVp)
Trial: 21299845
Drug: Intravenous darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF (n = 58)
Trial: 21299845
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF alone (n = 29)
Trial: 21299845
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n = 29)
Trial: 16758918
Drug: Chronopuncture as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronopuncture as a non-drug method of arterial pressure correction
Trial: 14691440
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (placebo group)
Trial: 9154757
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 15 micrograms acetylcholine chloride
Trial: 8089668
Drug: Vigabatrin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (1.5 g twice daily)
Trial: 3331395
Drug: Dexamethasone 0.36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.36 mg/kg/day for 9 days (group S)
Trial: 3331395
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group NS)
Trial: 25559324
Drug: PegIFN/RBV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN/RBV plus faldaprevir (120 mg, once daily for 12 or 24 weeks) (arm 2)
Trial: 25559324
Drug: PegIFN/RBV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN/RBV plus faldaprevir (240 mg, once daily for 12 weeks) (arm 3)
Trial: 23007137
Drug: Active stretching
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active stretching program (12 weeks, 3 days/week, 180 seconds daily)
Trial: 19205171
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser stimulation treatment (5 mV, 650 nm, 20 minutes daily for 3 months)
Trial: 14598939
Drug: ST regimen
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST regimen (streptomycin 1 g/day i.m. for 15 days and tetracycline‐HCl 500 mg every 6 h orally for 45 days)
Trial: 14598939
Drug: SD regimen
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days)
Trial: 14598939
Drug: DR regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DR regimen (doxycycline 100 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Trial: 14598939
Drug: OR regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OR regimen (ofloxacin 200 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Trial: 14598939
Drug: SDR regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDR regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days plus rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Trial: 11379605
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose interferon (3 MU day‐1, twice weekly for 6 months)
Trial: 7911286
Drug: acrivastine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acrivastine (8 mg)
Trial: 7911286
Drug: terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine (120 mg)
Trial: 31345792
Drug: G-CSF-mobilized blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF-mobilized blood stem cell (G-PB) grafts
Trial: 26266385
Drug: Argon Plasma
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon Plasma Coagulation (APC) along with distilled water injection
Trial: 26266385
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water injection alone
Trial: 21810044
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 500 mg PLC
Trial: 21810044
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1000 mg PLC
Trial: 21810044
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 500 mg PLC twice a day over 7 days
Trial: 21810044
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 1000 mg PLC twice a day over 7 days
Trial: 19654097
Drug: Continued medical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medical management (proton pump inhibitors)
Trial: 15599861
Drug: Concomitant radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant radiotherapy and chemotherapy (RT-CT) - 226 patients; 70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and 5-fluorouracil (5FU)
Trial: 10669274
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia followed by an infusion of normal saline (Control)
Trial: 10669274
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with continuous epidural infusion of 2% lidocaine (Group II)
Trial: 10669274
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with K+M+B administered 10 min after 2% lidocaine injection and 30 min before skin incision (Group III)
Trial: 1307517
Drug: Inhaled aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aerosol of platelet activating factor (PAF)
Trial: 3834227
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro treatment with CUP membrane fragments
Trial: 24324048
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of perindopril-indapamide (4/1.25 mg)
Trial: 21148615
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m² i.v. every 21 days until disease progression)
Trial: 17702126
Drug: Long-term peroral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term peroral anticoagulation treatment for 6 to 12 months
Trial: 17702126
Drug: Three-month treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-month treatment period
Trial: 10669897
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: four tablets at 0, 8, 24 and 48 h (320 mg artemether, 1,920 mg benflumetol)
Trial: 10669897
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: two tablets at 0, 8, 24 and 48 h (160 mg artemether, 960 mg benflumetol)
Trial: 10669897
Drug: Regimen C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C: four tablets at 0, 8 and 24 h (240 mg artemether, 1,440 mg benflumetol)
Trial: 9534283
Drug: i.v. isoproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. isoproterenol infusion (low doses)
Trial: 9534283
Drug: i.v. isoproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. isoproterenol infusion (higher doses)
Trial: 1722935
Drug: barucainide (300-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: barucainide (300-400 mg/day)
Trial: 6799558
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and insulin
Trial: 6799558
Drug: Glucose, insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose, insulin and amino acids
Trial: 24363760
Drug: TPN (Total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN (Total Parenteral Nutrition)
Trial: 6799558
Drug: Energy supply
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy supply >120-130% of daily energy output
Trial: 27052991
Drug: Lanconone® (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanconone® (1000 mg)
Trial: 18833115
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with additional dosage of levodopa/DDC inhibitor
Trial: 15684256
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) injections (40,000 UI/week subcutaneously until Ht of 40%)
Trial: 15684256
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood donation (ABD) (RBC pack collected weekly as long as Ht was above 33%)
Trial: 15114293
Drug: i.v. Dextran-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. Dextran-40 infusion (Group I, n = 48)
Trial: 15114293
Drug: i.v. albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. albumin infusion (Group II, n = 48)
Trial: 10798009
Drug: Sugar excretion
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar excretion measurement
Trial: 7597269
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer
Trial: 2035777
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms of fentanyl administered prophylactically by the epidural route
Trial: 31721905
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% compound lidocaine cream (0.2 g/cm2)
Trial: 31721905
Drug: Morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine group (10 mg tablet)
Trial: 23429575
Drug: Combined optical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined optical and atropine treatment (COAT)
Trial: 21829015
Drug: Heparin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 1,000 U/ml (group 2)
Trial: 21829015
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 U/ml (group 1)
Trial: 21829015
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (1,000 U/ml and 5,000 U/ml)
Trial: 17728047
Drug: Cortisol administration
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol administration (50 mg)
Trial: 15170922
Drug: Anakinra 75
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 75 mg/day
Trial: 15170922
Drug: Anakinra 150
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 150 mg/day
Trial: 1975426
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of pentamidine every two weeks
Trial: 1975426
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of pentamidine every two weeks
Trial: 1975426
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of pentamidine every four weeks
Trial: 159510
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (40 microgram) administered as two puffs from a metered dose inhaler four times a day for one week (regular use)
Trial: 159510
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ipratropium bromide (40 microgram) given 2.5 hours before the test
Trial: 159510
Drug: Placebo (propellants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (propellants only) administered four times a day for one week (regular use)
Trial: 11563899
Drug: Mesoglycan, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan, 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally, as an adjunct to compression therapy and topical wound care.
Trial: 11563899
Drug: Placebo, as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, as an adjunct to compression therapy and topical wound care.
Trial: 9758288
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg twice daily for 5 days with 200 mg trovafloxacin once daily from day 3-5
Trial: 9758288
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 5 days with 200 mg trovafloxacin once daily from day 3-5
Trial: 7823272
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of metronidazole gel
Trial: 3245293
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera vaccine (3 administrations of microgranules)